Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.

Lee J, Youn K, Choi NK, Lee JH, Kang D, Song HJ, Park BJ.

J Gastroenterol. 2013 Sep;48(9):1016-22. doi: 10.1007/s00535-012-0722-9. Epub 2013 Jan 11.

PMID:
23307040
[PubMed - indexed for MEDLINE]
2.

Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.

Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J.

Eur J Gastroenterol Hepatol. 2011 Sep;23(9):794-800. doi: 10.1097/MEG.0b013e328348a56a. Review.

PMID:
21701389
[PubMed - indexed for MEDLINE]
3.

[Atypical subtrochanteric fractures after long-term bisphosphonate therapy].

Czerwiński E.

Endokrynol Pol. 2011;62 Suppl 2:42-5. Review. Polish.

PMID:
22125022
[PubMed - indexed for MEDLINE]
4.

Atypical subtrochanteric fractures after long-term bisphosphonate therapy.

Czerwiński E.

Endokrynol Pol. 2011 Jan-Feb;62(1):84-7. Review.

PMID:
21365585
[PubMed - indexed for MEDLINE]
Free Article
5.

Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.

Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K.

Am J Gastroenterol. 2011 Jul;106(7):1209-18; quiz 1219. doi: 10.1038/ajg.2011.113. Epub 2011 Apr 12. Review.

PMID:
21483462
[PubMed - indexed for MEDLINE]
6.

Proton pump inhibitors and bone fractures?

Laine L.

Am J Gastroenterol. 2009 Mar;104 Suppl 2:S21-6. doi: 10.1038/ajg.2009.48. Review.

PMID:
19262543
[PubMed - indexed for MEDLINE]
7.

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C.

Osteoporos Int. 2011 Feb;22(2):373-90. doi: 10.1007/s00198-010-1453-5. Epub 2010 Nov 18. Review.

PMID:
21085935
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Fracture risk associated with chronic use of bisphosphonates: evidence today.

Charopoulos I, Orme S, Giannoudis PV.

Expert Opin Drug Saf. 2011 Jan;10(1):67-76. doi: 10.1517/14740338.2010.517192. Epub 2010 Dec 2. Review.

PMID:
21121870
[PubMed - indexed for MEDLINE]
9.

Proton pump-inhibiting drugs, calcium homeostasis, and bone health.

Wright MJ, Proctor DD, Insogna KL, Kerstetter JE.

Nutr Rev. 2008 Feb;66(2):103-8. doi: 10.1111/j.1753-4887.2008.00015.x. Review.

PMID:
18254877
[PubMed - indexed for MEDLINE]
10.

Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?

Yoon RS, Hwang JS, Beebe KS.

J Bone Joint Surg Br. 2011 Oct;93(10):1289-95. doi: 10.1302/0301-620X.93B10.26924. Review.

PMID:
21969423
[PubMed - indexed for MEDLINE]
11.

[Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].

Mawatari T.

Clin Calcium. 2010 Nov;20(11):1743-7. Review. Japanese. No abstract available.

PMID:
21066910
[PubMed - indexed for MEDLINE]
12.

Disentangling the emerging evidence around atypical fractures.

Abrahamsen B, Clark EM.

Curr Rheumatol Rep. 2012 Jun;14(3):212-6. doi: 10.1007/s11926-012-0241-y. Review.

PMID:
22359230
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk